Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in California: - UCSF at Berkeley Outpatient Center — Berkeley, California
- Alta Bates Summit Medical Center-Herrick Campus Comprehensive Cancer Center — Berkeley, California
- Palo Alto Medical Foundation - Fremont Center — Fremont, California
- Palo Alto Medical Foundation - Palo Alto Center — Palo Alto, California
- Roseville Medical Plaza Care Center — Roseville, California
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- Mission Hope Medical Oncology - Santa Maria — Santa Maria, California
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in California: - Clinical Study Site — Beverly Hills, California
- Clinical Study Site — Beverly Hills, California
- Clinical Study Site — Cerritos, California
- Clinical Study Site — Corona, California
- Clinical Study Site — Duarte, California
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in California: - CBCC Global Research — Bakersfield, California
- Los Angeles Cancer Network — Glendale, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA — Santa Monica, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in California: - Memorial Care Orange Coast Medical Center — Fountain Valley, California
- Providence Medical Foundation — Fullerton, California
- Cancer & Blood Research Center — Los Alamitos, California
- University of California Los Angeles Health — Los Angeles, California
Phase 3 Recruiting Industry
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…
Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in California: - GSK Investigational Site — Los Angeles, California
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in California: - USC/Norris Comprehensive Cancer Center — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center — Orange, California
- Local Institution - 0317 — San Francisco, California
- Local Institution - 0330 — Santa Monica, California
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in California: - Los Angeles Hematology Oncology Medical Group ( Site 0084) — Los Angeles, California
- UCLA Hematology/Oncology - Santa Monica ( Site 0088) — Santa Monica, California
Phase 3 Recruiting Industry
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…
Sponsor: Amgen
NCT ID: NCT06252649
Sites in California: - Providence Saint Jude Medical Center — Fullerton, California
- City of Hope National Medical Center — Long Beach, California
- Cancer and Blood Research Center, LLC — Los Alamitos, California
- California Research Institute — Los Angeles, California
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in California: - City of Hope — Arcadia, California
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in California: - Local Institution - 2129 — Duarte, California
- Local Institution - 2120 — Glendale, California
- Local Institution - 2136 — La Jolla, California
- Local Institution - 2114 — La Jolla, California
- Local Institution - 2121 — Long Beach, California
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sansum Clinic — Santa Barbara, California
- Providence Medical Foundation — Santa Rosa, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
- UCLA Hematology/Oncology- Santa Monica — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in California: - University of California, Los Angeles (UCLA) — Los Angeles, California
- Stanford Cancer Institute, Stanford University — Palo Alto, California
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Sarcoma Oncology Center — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in California: - UCSD — La Jolla, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sharp Healthcare — San Diego, California
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in California: - The Oncology Institute of Hope and Innovation — Cerritos, California
- Ellison Medical Institute — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California Los Angeles — Los Angeles, California
- University of California Irvine — Orange, California
Phase 2 Recruiting Industry
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…
Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in California: - Central Recruiting Site — Fair Oaks, California
- Central Recruiting Site — Fountain Valley, California
- Central Recruiting Site — Los Angeles, California
- Central Recruiting Site — Santa Rosa, California
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in California: - City of Hope — Duarte, California
- UC IRVINE Health — Orange, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
- Stanford Cancer Institute — Stanford, California
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metasta…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691491
Sites in California: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in California: - Providence Medical Foundation - Fullerton /ID# 274207 — Fullerton, California
- USC Norris Comprehensive Cancer Center /ID# 274550 — Los Angeles, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- Lucile Packard Children's Hospital Stanford University — Palo Alto, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in California: - UC Irvine/Chao Family Comprehensive Cancer Center — Orange, California
- UCLA — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California: - Valkyrie Clinical Trials — Los Angeles, California
- Los Angeles Cancer Network — Los Angeles, California
- Pih Health Hematology Medical Oncology — Whittier, California